Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SONIA trial
2017-002334-23Phase 3Active
- Sponsor
- BOOG Study Group
- Start
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of fulvestrant in breast cancer (2 arms), sponsored by BOOG Study Group. Primary endpoint: Progression-free survival. Started Aug 2017; status: active.
02
Drugs
fulvestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2017-002334-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002334-23.